Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials

  title={Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials},
  author={Jun Shen and Zhixiang Zuo and Ai-ping Mao},
  journal={Inflammatory Bowel Diseases},
Background:Whether probiotics are beneficial at all stages of treatment in inflammatory bowel disease or superior to placebo remains controversial. Methods:Two reviewers independently selected randomized controlled trials comparing probiotics with controls in inflammatory bowel disease and extracted data related to remission/response rates, relapse rates, and adverse events. Subanalyses were also performed. Results:Twenty-three randomized controlled trials with a total of 1763 participants met… 

Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review

Probiotics in patients with Ulcerative colitis in different conditions have significant effects and in children with IBD, the combination of Lactobacillus with VSL#3 probiotics had significant effect, especially the combination ones in UC.

Probiotics for induction of remission in Crohn's disease.

The available evidence is very uncertain about the efficacy or safety of probiotics, when compared with placebo, for induction of remission in Crohn's disease, and further research is needed.

Probiotic Medilac-S® for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis

Evidence suggests Medilac-S® adjunctive therapy should be considered standard care for UC in a Chinese population because it aids in the induction of clinical remission, improves symptoms of the gastrointestinal tract and reduces risk of AEs.

Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial

A meta-analysis to evaluate the effect of probiotic combined with aminosalicylic on induction remission maintenance treatment of ulcerative colitis indicated that the remission rate was significantly higher in the group using probiotics combined withAminosalcylic acid than that in the groups using aminosAlicylic acid alone.

Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

The treatment of IBD with pro/pre/synbiotics, and synbiotics are more effective, and probiotic supplements that are based on Lactobacillus and Bifidobacterium or more than one strain are more likely to be beneficial for IBD remission.

The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis

It is concluded that a validated scale is necessary to determine the state of patients with UC and probiotics containing bifidobacteria are promising for the treatment of active UC.

Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease

There is evidence to support the use of probiotics for induction and maintenance of remission in UC and pouchitis, but there is insufficient data to recommend Probiotics for use in CD.

Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis: A Meta-analysis

VSL#3, when added to conventional therapy at a daily dose of 3.6 × 1012 CFU/d, is safe and more effective than conventional therapy alone in achieving higher response and remission rates in mild to moderately active ulcerative colitis.



Lactobacillus GG in inducing and maintaining remission of Crohn's disease

This study could not demonstrate a benefit of L. GG in inducing or maintaining medically induced remission in CD, and the primary end point was sustained remission, defined as freedom from relapse at the 6 months follow-up visit.

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study

VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants at stable doses.

Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis

This is the first pediatric, randomized, placebo-controlled, double-blind trial that suggests the efficacy and safety of a highly concentrated mixture of probiotic bacterial strains (VSL#3) in active UC and demonstrates its role in maintenance of remission.

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG

Lactobacillus GG seems neither to prevent endoscopic recurrence at one year nor reduce the severity of recurrent lesions in Crohn's disease.

A Randomized, Double‐blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohn's Disease

It is suggested that LGG does not prolong time to relapse in children with CD when given as an adjunct to standard therapy, and was well tolerated, with a side effect profile comparable with placebo.

Probiotics for induction of remission in Crohn's disease.

There is insufficient evidence to make any conclusions about the efficacy of probiotics for induction of remission in Crohn's disease and a lack of well designed RCTs in this area is needed.

Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection.

Oral administration of the probiotic LA1 in patients with CD failed to prevent early endoscopic recurrence at 12 weeks after ileo-caecal resection.

Probiotics in the Management of Inflammatory Bowel Disease

Further well designed studies based on intention-to-treat analyses by several independent research groups are still warranted to support the promising results for E. coli Nissle in inactive UC and the multispecies product VSL#3 in active UC and inactive pouch patients.

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial

The probiotic strain L johnsonii LA1 (4×109 cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn’s disease.